TriangleBiospecimen Collection (NCT06453044)
Biospecimen Collection trial for Recurrent Grade 1 Follicular Lymphoma (NCT06453044). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with CD20-positive grade-one to grade-three-A follicular lymphoma that returned or resisted at least one treatment line and needs treatment. Current transformed large-cell lymphoma excludes participation.
The idea: combine mosunetuzumab injections under the skin with polatuzumab vedotin infusions. Mosunetuzumab connects T cells to CD20-bearing lymphoma cells; polatuzumab carries a toxin to CD79B-bearing cells. Polatuzumab lasts up to six cycles; mosunetuzumab can continue longer. Researchers assess safety and complete responses, with imaging and tests.
This phase 2 study plans 41 patients. Matthew Mei leads City of Hope's recruiting Duarte site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.